Osamu Nureki
Fondatore presso MODALIS THERAPEUTICS CORPORATION
Patrimonio netto: 1 M $ in data 30/04/2024
Posizioni attive di Osamu Nureki
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Direttore/Membro del Consiglio | 01/01/2016 | - |
| Fondatore | 01/01/2016 | - | |
Curreio, Inc.
 Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Direttore/Membro del Consiglio | 01/11/2019 | - |
| University of Tokyo | Corporate Officer/Principal | 01/04/2008 | - |
Storia della carriera di Osamu Nureki
Formazione di Osamu Nureki
| University of Tokyo | Graduate Degree |
Statistiche
Distribuzione geografica
| Giappone | 4 |
Posizioni
| Director/Board Member | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |
- Borsa valori
- Insiders
- Osamu Nureki
- Esperienza
